Anders Lonner - Karo Pharma Insider

Karo Pharma AB -- USA Stock  

USD 4.10  4.10  9,223,372,036,855%

Chairman of the Board

Mr. Anders Lonner was Executive Chairman of the Board of Directors of Karo Pharma AB since February 4, 2015. He has previously been Independent Chairman of the Board since May 8, 2014. He holds MS in Political Science degree. He was previously Chief Executive Officer and President for Meda AB and had before then been CEO for Astra Lakemedel with responsibility for, among other things, Astras Nordic subsidiaries, CEO in Karo Bio AB and President of Lakemedelsforeningen. He is Advisor for EQT. In 2014 he was nominated Honorary Doctor of Medicine at Karolinska Institutet.
Age: 72  Chairman Since 2015      
46 86 08 60 00

Management Efficiency

The company has return on total asset (ROA) of 4.14 % which means that it generated profit of $4.14 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 16.6 % meaning that it generated $16.6 on every $100 dollars invested by stockholders.
The company has accumulated 77.45 M in total debt with debt to equity ratio (D/E) of 58.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karo Pharma AB has Current Ratio of 2.06 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 2 records


Jeffrey BezosAmazon com Inc
John ThompsonMicrosoft Corporation

Entity Summary

Karo Pharma AB , a pharmaceutical company, develops various drugs in Sweden. Karo Pharma AB (KARBF) is traded on OTC Market in USA. It is located in Stockholm, and employs 39 people.

Did you try this?

Run Equity Forecasting Now

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
Hide  View All  NextLaunch Equity Forecasting
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Karo Pharma AB to your portfolio

Top Management

Karo Pharma AB Leadership Team
PerAnders Johansson, Director
Jean Lycke, Director
Per Johansson, Executive
Peter Blom, CEO
Henrik Palm, CFO
Anders Lonner, Chairman
Marianne Hamilton, Director
Maria Sjoberg, President
Hakan Astrom, Director
Thomas Kraft, Executive
Goran Wessman, Director
Bo Carlsson, Executive
Thomas Hedner, Director, MBA

Stock Performance

Karo Pharma Performance Indicators